HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Mark R Lackner Selected Research

Class I Phosphatidylinositol 3-Kinases

1/2014Targeted biomarker profiling of matched primary and metastatic estrogen receptor positive breast cancers.
7/2010Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Mark R Lackner Research Topics

Disease

39Neoplasms (Cancer)
01/2020 - 07/2008
22Breast Neoplasms (Breast Cancer)
01/2020 - 07/2008
4Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
01/2019 - 04/2012
3Disease Progression
01/2020 - 11/2016
3Colorectal Neoplasms (Colorectal Cancer)
01/2019 - 08/2009
3Lung Neoplasms (Lung Cancer)
01/2019 - 12/2011
3Melanoma (Melanoma, Malignant)
01/2018 - 12/2011
3Circulating Neoplastic Cells
04/2012 - 09/2010
2Ovarian Epithelial Carcinoma
07/2015 - 01/2015
1Prostatic Neoplasms (Prostate Cancer)
01/2020
1Neoplasm Metastasis (Metastasis)
01/2019
1Adrenal Gland Neoplasms (Adrenal Cancer)
01/2018
1Endometrial Neoplasms (Endometrial Cancer)
11/2016
1Renal Cell Carcinoma (Grawitz Tumor)
10/2016
1Hyperglycemia
10/2016
1Exanthema (Rash)
10/2016
1Hypoxia (Hypoxemia)
10/2016
1Urinary Bladder Neoplasms (Bladder Cancer)
01/2016
1Ovarian Neoplasms (Ovarian Cancer)
07/2015
1Multiple Myeloma
03/2013
1Hematologic Neoplasms (Hematological Malignancy)
03/2013
1Colonic Neoplasms (Colon Cancer)
06/2012
1Pancreatic Neoplasms (Pancreatic Cancer)
12/2011
1Genomic Instability
04/2009
1Neuroblastoma
09/2008

Drug/Important Bio-Agent (IBA)

18Biomarkers (Surrogate Marker)IBA
01/2020 - 07/2008
8Estrogen ReceptorsIBA
01/2020 - 08/2009
8Proteins (Proteins, Gene)FDA Link
10/2016 - 12/2008
7Phosphatidylinositol 3-Kinase (1 Phosphatidylinositol 3 Kinase)IBA
01/2020 - 07/2009
62- (1H- indazol- 4- yl)- 6- (4- methanesulfonylpiperazin- 1- ylmethyl)- 4- morpholin- 4- ylthieno(3,2- d)pyrimidineIBA
12/2017 - 07/2010
6Phenobarbital (Luminal)FDA Link
10/2016 - 07/2008
5Formaldehyde (Formol)FDA Link
01/2019 - 01/2014
5ParaffinIBA
01/2019 - 01/2014
4DNA (Deoxyribonucleic Acid)IBA
01/2019 - 07/2009
4Mitogen-Activated Protein Kinase Kinases (MEKs)IBA
01/2018 - 07/2009
4Phosphotransferases (Kinase)IBA
01/2012 - 12/2008
3Phosphoric Monoester Hydrolases (Phosphatases)IBA
11/2016 - 04/2009
3TensinsIBA
11/2016 - 04/2009
3TOR Serine-Threonine KinasesIBA
11/2016 - 12/2011
23- (4- (2- (2- chloro- 4- fluorophenyl)- 1- (1H- indazol- 5- yl)but- 1- en- 1- yl)phenyl)acrylic acidIBA
01/2019 - 01/2016
2Erlotinib Hydrochloride (CP 358,774)FDA Link
12/2017 - 04/2012
2ErbB Receptors (EGF Receptor)IBA
12/2017 - 06/2011
2Circulating Tumor DNAIBA
11/2017 - 04/2012
2Progesterone Receptors (Progesterone Receptor)IBA
10/2016 - 11/2014
2Pharmaceutical PreparationsIBA
01/2016 - 01/2012
2RNA (Ribonucleic Acid)IBA
01/2016 - 11/2014
2Docetaxel (Taxotere)FDA Link
10/2015 - 09/2008
2PlatinumIBA
07/2015 - 01/2015
2Messenger RNA (mRNA)IBA
11/2014 - 01/2014
2Class I Phosphatidylinositol 3-KinasesIBA
01/2014 - 07/2010
2MitogensIBA
05/2012 - 06/2011
2Extracellular Signal-Regulated MAP Kinases (Extracellular Signal Regulated Kinases)IBA
05/2012 - 07/2009
2Protein Kinases (Protein Kinase)IBA
01/2012 - 06/2011
2Insulin-Like PeptidesIBA
05/2010 - 09/2008
2Monoclonal AntibodiesIBA
08/2009 - 09/2008
2IGF Type 1 Receptor (IGF 1 Receptor)IBA
08/2009 - 09/2008
1AndrogensIBA
01/2020
1Hormones (Hormone)IBA
01/2020
12- (3- (2- (1- isopropyl- 3- methyl- 1H- 1,2- 4- triazol- 5- yl)- 5,6- dihydrobenzo(f)imidazo(1,2- d)(1,4)oxazepin- 9- yl)- 1H- pyrazol- 1- yl)- 2- methylpropanamideIBA
01/2020
1Biological ProductsIBA
01/2019
1Cell-Free Nucleic AcidsIBA
01/2019
1cobimetinibIBA
01/2018
1VemurafenibIBA
01/2018
1Tyrosine Kinase InhibitorsIBA
12/2017
1EverolimusFDA Link
10/2016
1human ERBB2 proteinIBA
10/2016
1Mechanistic Target of Rapamycin Complex 1IBA
10/2016
1Anastrozole (Arimidex)FDA LinkGeneric
10/2016
1Fulvestrant (Faslodex)FDA Link
01/2016
1Aromatase InhibitorsIBA
01/2016
1TamoxifenFDA LinkGeneric
01/2016
1Cyclophosphamide (Cytoxan)FDA LinkGeneric
10/2015
1Capecitabine (Xeloda)FDA Link
10/2015
1Doxorubicin (Adriamycin)FDA LinkGeneric
10/2015
1PeriostinIBA
07/2015
1Trastuzumab (Herceptin)FDA Link
05/2015
1Ribosomal Proteins (Ribosomal Protein)IBA
01/2015
1Epidermal Growth Factor (EGF)IBA
11/2014
1SolutionsIBA
04/2014
1Matrix Metalloproteinases (MMPs)IBA
04/2014
1ipatasertibIBA
12/2013
1onartuzumabIBA
06/2013
1Hepatocyte Growth Factor (Growth Factor, Hepatocyte)IBA
06/2013
1Phosphatidylinositols (Phosphatidylinositol)IBA
12/2012
1CateninsIBA
06/2012
1pertuzumabIBA
04/2012
11- (4- ((2- (2- aminopyrimidin- 5- yl)- 7- methyl- 4- morpholinothieno(3,2- d)pyrimidin- 6- yl)methyl)piperazin- 1- yl)- 2- hydroxypropan- 1- oneIBA
12/2011
1MTOR InhibitorsIBA
12/2011
1Transcription Factors (Transcription Factor)IBA
06/2011
1MicroRNAs (MicroRNA)IBA
06/2011
1Epithelial Cell Adhesion MoleculeIBA
09/2010
1Tumor Biomarkers (Tumor Markers)IBA
09/2010
1Estrogen Receptor Modulators (Antiestrogen)IBA
08/2009
1Insulin-Like Growth Factor II (Somatomedin A)IBA
09/2008

Therapy/Procedure

10Therapeutics
10/2016 - 07/2009
2Adjuvant Chemotherapy
01/2019 - 01/2016
2Drug Therapy (Chemotherapy)
11/2016 - 07/2015
2Precision Medicine
01/2016 - 04/2014
1Castration
01/2020
1Immunotherapy
01/2019